Georgia's Online Cancer Information Center


back

Head and Neck Cancer Clinical Trials in Georgia

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.
Cancer Type = Head and Neck Cancer
Cancer Type = Head and Neck Cancer
NCI ID Cancer Type Trial Name
There are currently 42 active Head and Neck Cancer clinical trials in Georgia.
NCI ID Cancer Type Trial Name
1.
A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1
Cancer Type
Head and Neck Cancer
NCT ID
NCT04534205
Protocol IDs
BNT113-01
NCI-2021-03177
2020-001400-41
2.
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of Avelumab (MSB0010718C) in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
Cancer Type
Head and Neck Cancer
NCT ID
NCT01772004
Protocol IDs
EMR 100070-001
2013-002834-19
Treatment Sites (1)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
3.
A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer)
Cancer Type
Head and Neck Cancer, Skin Cancer (Non-Melanoma), Unknown Primary
NCT ID
NCT05459129
Protocol IDs
CO43613
NCI-2022-06114
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
4.
A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies
Cancer Type
Bladder Cancer, Breast Cancer, Colon/Rectal Cancer, Head and Neck Cancer, Kidney Cancer, Lung Cancer, Ovarian Cancer, Unknown Primary
NCT ID
NCT06120075
Protocol IDs
ARC-27
NCI-2024-03901
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
5.
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
Cancer Type
Head and Neck Cancer, Skin Cancer (Non-Melanoma), Unknown Primary
NCT ID
NCT06064877
Protocol IDs
AV-299-23-301
NCI-2024-00596
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
6.
A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
Cancer Type
Head and Neck Cancer
NCT ID
NCT04974398
Protocol IDs
AK105-304
NCI-2022-08325
Treatment Sites (2)
City of Hope Atlanta
Newnan
Brian Wortz, PharmD, ACRP-CP
770-400-6169
Winship Cancer Institute of Emory University
Atlanta
7.
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)
Cancer Type
Brain & Spinal Cord Tumor, Colon/Rectal Cancer, Head and Neck Cancer, Lung Cancer, Neuroendocrine Tumor, Solid Tumor, Thyroid Cancer, Unknown Primary
NCT ID
NCT03157128
Protocol IDs
LOXO-RET-17001
NCI-2017-00976
2017-000800-59
Treatment Sites (1)
Emory University School of Medicine
Atlanta
8.
Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC
Cancer Type
Head and Neck Cancer
NCT ID
NCT05814666
Protocol IDs
FLM-6774-201
NCI-2023-08785
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
9.
ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed At Least Two Lines of Therapy
Cancer Type
Head and Neck Cancer, Skin Cancer (Non-Melanoma), Unknown Primary
NCT ID
NCT03769506
Protocol IDs
ASP-1929-301
NCI-2019-01324
10.
Atezolizumab for the Treatment of Patients with Resectable, Human Papillomavirus Related Oropharyngeal Squamous Cell Carcinoma
Cancer Type
Head and Neck Cancer, Unknown Primary
NCT ID
NCT06254911
Protocol IDs
WINSHIP5730-22
NCI-2023-01367
STUDY00004678
Treatment Sites (2)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
11.
Biomarker-Driven Radiation Therapy Dose Reduction after Transoral Robotic Surgery for the Treatment of HPV-Positive Oropharyngeal Cancer
Cancer Type
Head and Neck Cancer, Unknown Primary
NCT ID
NCT05387915
Protocol IDs
WINSHIP5566-22
NCI-2022-02855
STUDY00004187
Treatment Sites (2)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
12.
NCORP Trial
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
Cancer Type
Bladder Cancer, Breast Cancer, Cervical Cancer, Colon/Rectal Cancer, Esophogeal Cancer, Head and Neck Cancer, Leukemia, Lung Cancer, Lymphoma, Multiple Myeloma, Ovarian Cancer, Prostate Cancer , Sarcoma, Solid Tumor, Stomach/ Gastric Cancer, Thyroid Cancer
NCT ID
NCT05366881
Protocol IDs
Adela-EDMRD-001
NCI-2022-04272
Treatment Sites (1)
Northeast Georgia Medical Center - Gainesville
Gainesville
Trena Davis
770-219-8822
13.
Collecting Blood Samples from Patients with and without Cancer to Evaluate Tests for Early Cancer Detection
Cancer Type
Breast Cancer, Head and Neck Cancer, Hematopoietic Malignancies, Kidney Cancer, Leukemia, Melanoma, Sarcoma, Solid Tumor, Thyroid Cancer, Unknown Primary
NCT ID
NCT05334069
Protocol IDs
A212102
A212102
A212102
NCI-2022-02477
Treatment Sites (1)
Low Country Cancer Care Associates, PC
Savannah
14.
Combining Radiation Therapy with Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck
Cancer Type
Head and Neck Cancer, Skin Cancer (Non-Melanoma), Unknown Primary
NCT ID
NCT05721755
Protocol IDs
EA3211
EA3211
NCI-2022-10141
Treatment Sites (1)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
15.
Comparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined with Radiation for Patients with Advanced Head and Neck Cancer
Cancer Type
Head and Neck Cancer, Skin Cancer (Non-Melanoma), Unknown Primary
NCT ID
NCT05050162
Protocol IDs
NRG-HN009
NRG-HN009
NCI-2021-08925
Treatment Sites (1)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
16.
Comparing Sentinel Lymph Node (SLN) Biopsy with Standard Neck Dissection for Patients with Early-Stage Oral Cavity Cancer
Cancer Type
Head and Neck Cancer
NCT ID
NCT04333537
Protocol IDs
NRG-HN006
NRG-HN006
NCI-2020-01542
17.
Decision Support Training for Family Caregivers of Patients with Advanced Cancer, CASCADE Factorial Study
Cancer Type
Breast Cancer, Head and Neck Cancer, Lung Cancer, Melanoma
NCT ID
NCT04803604
Protocol IDs
XUAB2122
NCI-2023-00872
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
18.
De-intensified Radiation Therapy with Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients with Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer
Cancer Type
Head and Neck Cancer, Unknown Primary
NCT ID
NCT03952585
Protocol IDs
NRG-HN005
NRG-HN005
NCI-2019-03015
Treatment Sites (2)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Grady Memorial Hospital
Atlanta
19.
Head and Neck cancERs International cOviD-19 collabOraTion
Cancer Type
COVID-19, Head and Neck Cancer, Thyroid Cancer
NCT ID
NCT04632173
Protocol IDs
HERODOTUS
NCI-2021-11878
20.
Implementation and Effectiveness of HN-STAR in Managing the Health of Head and Neck Squamous Cell Cancer Survivors
Cancer Type
Head and Neck Cancer
NCT ID
NCT04208490
Protocol IDs
WF-1805CD
WF-1805CD
WF-1805CD
NCI-2019-03600
Treatment Sites (1)
Phoebe Cancer Center at Phoebe Putney Memorial Hospital
Albany
Dept of Clinical Research
229-312-5091
21.
Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)
Cancer Type
Head and Neck Cancer, Skin Cancer (Non-Melanoma), Unknown Primary
NCT ID
NCT04428151
Protocol IDs
7902-009
NCI-2020-04563
2019-000569-19
E7080-G000-228
LEAP-009
MK-7902-009
22.
Pembrolizumab and Cabozantinib in Treating Patients with Recurrent or Metastatic Head and Neck Squamous Cell Cancer That Cannot Be Removed by Surgery
Cancer Type
Head and Neck Cancer
NCT ID
NCT03468218
Protocol IDs
Winship4234-17
NCI-2017-02419
IRB00100269
Treatment Sites (1)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
23.
Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Cancer Type
Head and Neck Cancer
NCT ID
NCT04815720
Protocol IDs
VX15/2503-12
NCI-2021-10364
KEYNOTE B84
24.
Pepinemab with or without Ipilimumab and/or Nivolumab in Treating Patients with Stage I-IVA Head and Neck Squamous Cell Cancer
Cancer Type
Head and Neck Cancer, Skin Cancer (Non-Melanoma), Unknown Primary
NCT ID
NCT03690986
Protocol IDs
Winship4402-18
NCI-2018-01263
IRB00103534
Treatment Sites (1)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
25.
Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies
Cancer Type
Head and Neck Cancer, Sarcoma, Solid Tumor
NCT ID
NCT04541108
Protocol IDs
PBI-MST-01
NCI-2021-10892
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
26.
Phase 1a/1b Study of STK-012 Monotherapy and in Combination With Pembrolizumab in Patients With Solid Tumors
Cancer Type
Brain & Spinal Cord Tumor, Head and Neck Cancer, Kidney Cancer, Lung Cancer, Melanoma, Ovarian Cancer, Solid Tumor, Unknown Primary
NCT ID
NCT05098132
Protocol IDs
STK-012-101
NCI-2022-00633
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
27.
Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally Advanced Resected Head and Neck Cancer
Cancer Type
Head and Neck Cancer
NCT ID
NCT01311063
Protocol IDs
RTOG0920-VA
RAC# 2101-074
Treatment Sites (1)
Atlanta VA Medical Center
Decatur
Scott Edelman
404-728-7680
28.
Radiation Therapy with or without Cisplatin in Treating Patients with Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
Cancer Type
Head and Neck Cancer
NCT ID
NCT02734537
Protocol IDs
EA3132
NCI-2015-01911
Treatment Sites (2)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
29.
Safety and Efficacy of Repeat Administration of Ad/PNP and Fludarabine Phosphate in Patients With Local Head/Neck Cancer
Cancer Type
Head and Neck Cancer
NCT ID
NCT03754933
Protocol IDs
PNP-002
NCI-2019-01328
14271
R01FD005746-01A1
30.
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
Cancer Type
Breast Cancer, Colon/Rectal Cancer, Head and Neck Cancer, Liver Cancer / Hepatoblastoma, Lung Cancer, Melanoma, Ovarian Cancer, Sarcoma, Stomach/ Gastric Cancer
NCT ID
NCT04140526
Protocol IDs
ONC-392-001
R44CA250824-01
NCI-2020-06149
20193108
4R44CA250824-02
31.
Study of CHS-114 in Participants With Advanced Solid Tumors
Cancer Type
Head and Neck Cancer, Skin Cancer (Non-Melanoma), Solid Tumor, Unknown Primary
NCT ID
NCT05635643
Protocol IDs
SRF114-101
NCI-2023-05019
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
32.
Study of SGN1 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumor
Cancer Type
Cervical Cancer, Head and Neck Cancer, Liver Cancer / Hepatoblastoma, Melanoma, Sarcoma, Skin Cancer (Non-Melanoma), Solid Tumor, Unknown Primary
NCT ID
NCT05103345
Protocol IDs
SGN-P01-002
NCI-2023-06281
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
33.
Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Cancer Type
Head and Neck Cancer, Unknown Primary
NCT ID
NCT06082167
Protocol IDs
XL092-305
NCI-2024-03938
EU CTR: 2023-506308-24-00
Treatment Sites (1)
University Cancer and Blood Center, LLC - Athens Medical Oncology
Athens
34.
NCORP Trial
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
Cancer Type
Head and Neck Cancer, Unknown Primary
NCT ID
NCT01810913
Protocol IDs
RTOG 1216
NCI-2013-00500
U10CA021661
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
35.
NCORP Trial
Testing Immunotherapy versus Observation in Patients with HPV Throat Cancer
Cancer Type
Head and Neck Cancer, Unknown Primary
NCT ID
NCT03811015
Protocol IDs
EA3161
EA3161
NCI-2019-00179
Treatment Sites (4)
Atlanta VA Medical Center
Decatur
Scott Edelman
404-728-7680
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
Winship Cancer Institute of Emory University
Atlanta
36.
Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients with Advanced Head and Neck Cancer Who Cannot Take Cisplatin
Cancer Type
Head and Neck Cancer, Unknown Primary
NCT ID
NCT04533750
Protocol IDs
NRG-HN008
NRG-HN008
NCI-2020-06481
37.
Testing the Anti-Cancer Drug Darolutamide in Patients with Testosterone-driven Salivary Gland Cancers
Cancer Type
Head and Neck Cancer
NCT ID
NCT05669664
Protocol IDs
10553
10553
NCI-2022-10701
Treatment Sites (1)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
38.
Testing the use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy with Docetaxel plus Trastuzumab) for Recurrent, Metastatic, or Unresectable HER2-Positive Salivary Gland Cancer
Cancer Type
Head and Neck Cancer
NCT ID
NCT05408845
Protocol IDs
NRG-HN010
NRG-HN010
NCI-2022-04353
Treatment Sites (1)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
39.
Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab with or without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers
Cancer Type
Head and Neck Cancer
NCT ID
NCT05063552
Protocol IDs
EA3202
EA3202
NCI-2021-10021
Treatment Sites (2)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
40.
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy with Radiation after Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
Cancer Type
Head and Neck Cancer, Unknown Primary
NCT ID
NCT04671667
Protocol IDs
EA3191
EA3191
NCI-2020-13174
41.
Tolinapant and Radiation Therapy for the Treatment of Cisplatin-Ineligible, Previously Untreated, Locally Advanced Head and Neck Cancer
Cancer Type
Head and Neck Cancer
NCT ID
NCT05245682
Protocol IDs
WINSHIP5380-21
NCI-2021-09678
STUDY00002992
42.
Use of Lymphatic Mapping to Guide Radiotherapy to the Neck in Oropharyngeal Cancer
Cancer Type
Head and Neck Cancer, Unknown Primary
NCT ID
NCT05451004
Protocol IDs
CCTG-HN11
CCTG-HN11
NCI-2022-04496
Treatment Sites (1)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
About Us Research Resources & Education Screening & Genetics Clinical Trials & Providers Cancer Navigators Survivorship Media, News & Events Contact Us Donate Take Our Survey Link to Us

Research

Screening & Genetics

Find Cancer Care

Survivorship

About Georgia CORE

Education & Resources

Media, News & Events

Patient Navigation

Georgia CORE

 

Georgia CORE bridges the gap between groundbreaking research, educational outreach, and effective advocacy to transform the landscape of cancer care for all Georgians.